195 related articles for article (PubMed ID: 1495553)
21. Rising costs hold up drug discovery.
Miller HI
Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
[No Abstract] [Full Text] [Related]
22. FDA launches priority vouchers for neglected-disease drugs.
Waltz E
Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
[No Abstract] [Full Text] [Related]
23. Fake biotech drugs raise concerns.
Fox JL
Nat Biotechnol; 2001 Jul; 19(7):603. PubMed ID: 11433258
[No Abstract] [Full Text] [Related]
24. FDA dependence on drug industry.
Lawson GW
J Natl Med Assoc; 2005 Jul; 97(7):1039-40. PubMed ID: 16080677
[No Abstract] [Full Text] [Related]
25. How the street sees biotech.
Lashinsky A
Fortune; 2003 Jun; 147(11):86. PubMed ID: 12800576
[No Abstract] [Full Text] [Related]
26. Foreign Establishment Registration and United States agent requirements.
Nolte CJ; McNamara-Cullinane M
Med Device Technol; 2002 Dec; 13(10):32-3. PubMed ID: 12575528
[TBL] [Abstract][Full Text] [Related]
27. Nasdaq restructures biotech index.
Morrison C
Nat Biotechnol; 2001 Mar; 19(3):187. PubMed ID: 11231518
[No Abstract] [Full Text] [Related]
28. This Dutchman is flying.
Watson N
Fortune; 2003 Jun; 147(13):89-90. PubMed ID: 12827720
[No Abstract] [Full Text] [Related]
29. Growing pains for biopharmaceuticals.
Ashton G
Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
[No Abstract] [Full Text] [Related]
30. Public biotech 98: the numbers.
Lähteenmäki R; Michael A; Marshall A
Nat Biotechnol; 1999 May; 17(5):429-32. PubMed ID: 10331795
[No Abstract] [Full Text] [Related]
31. Biotech industry struggles with generics approval.
Knight J
Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
[No Abstract] [Full Text] [Related]
32. The biotech drug market.
Lawrence S
Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
[No Abstract] [Full Text] [Related]
33. User fees advance in Congress.
Gershon D
Nature; 1992 Sep; 359(6393):261. PubMed ID: 1406918
[No Abstract] [Full Text] [Related]
34. Biotech companies adapt to big pharma mergers.
Niiler E
Nat Biotechnol; 2000 May; 18(5):487-8. PubMed ID: 10802607
[No Abstract] [Full Text] [Related]
35. HHS: POUFA reauthorization good for Americans.
FDA Consum; 2002; 36(5):5. PubMed ID: 12412536
[No Abstract] [Full Text] [Related]
36. A special biotech speculation.
Jacobs T
Nat Biotechnol; 2006 Jun; 24(6):622. PubMed ID: 16763586
[No Abstract] [Full Text] [Related]
37. Polio endgame. Wanted: drug for a disappearing disease.
Enserink M
Science; 2004 Mar; 303(5666):1971. PubMed ID: 15044783
[No Abstract] [Full Text] [Related]
38. Investing in risk management.
Fiscus PW
Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
[No Abstract] [Full Text] [Related]
39. 25 breakout companies--biotech: Sirtris Pharmaceuticals, Bacterin, XDX.
Stipp D; Boyle M; Stires D
Fortune; 2005 May; 151(10):169. PubMed ID: 15931765
[No Abstract] [Full Text] [Related]
40. Repeal law that puts "FDA on the payroll of the industry," says former NEJM editor.
Kmietowicz Z
BMJ; 2007 Mar; 334(7591):447. PubMed ID: 17332569
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
